ERBB2 and breast carcinoma: In this study we used ERBB2d16/ERBB2 ratio to indicate and differentiate the expression of ERBB2d16 for the first time and found that high expression of ERBB2d16 was related to EMT and resistance to trastuzumab, which was consistent with the previous study in breast cancer.